表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌相关不良反应研究进展

表皮生长因子受体酪氨酸激酶抑制剂（EGFR—TKI）治疗非小细胞肺癌（NSCLC）有较好疗效，目前临床常用药物为吉非替尼，厄洛替尼和埃克替尼。随着EGFR—TKI在临床的广泛应用，关于其不良反应的研究也不断深入。EGFR—TKI主要不良反应为皮疹、甲沟炎、毛发改变、腹泻、肝脏损害和间质性肺疾病等。引起不良反应的机制大多不明确。对于较常见的皮疹、甲沟炎等不良反应，较轻时可给予对症处理，严重时应减量或停药；对于较严重的肝脏损害或间质性肺疾病，给予对症治疗的同时要定期检测肝、肺功能。

Research progress in adverse drug reactions associated with epidermal growth factor receptor-tyrosine kinase inhibitors therapy for non-small-cell lung cancer: a review

The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors （EGFR-TKI） is good in treatment for non-small-cell lung cancer. The commonly used EGFR-TKI in clinical are gefitinib, erlotinib, and icotinib in the present. With the wide application of EGFR-TKI, adverse drug reactions （ADR） associated with EGFR-TKI are studied deeply. The main ADR associated with EGFR-TKI are rash, paronychia, hair alterations, diarrhea, liver damage, interstitial lung disease, and so on. The mechanisms that lead to these adverse reactions are not clear. Symptomatic treatments should be given when the symptoms are mild and the dosage of EGFR-TKI should be reduced or withdrawn when the symptoms are severe in patients with more common adverse reactions such as rash and paronychia. Symptomatic therapy should be given and functions of the liver and lungs should be monitored regularly in patients with more serious liver damage or interstitial lung disease.